Common treatment of certain autoimmune disease does not appear effective

July 15, 2014

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA.

Primary Sjögren is characterized by mouth and eye dryness, pain, and fatigue, with systemic manifestations occurring in approximately one-third of . Despite the wide use of in clinical practice, evidence regarding its efficacy is limited, according to background information in the article.

Jacques-Eric Gottenberg, M.D., Ph.D., of the Universite de Strasbourg, Strasbourg, France, and colleagues randomly assigned 120 patients with primary Sjögren syndrome to receive hydroxychloroquine or placebo for 24 weeks. All patients (treatment and placebo) were prescribed hydroxychloroquine between weeks 24 and 48. The study was conducted at 15 university hospitals in France.

At 24 weeks, the proportion of patients meeting the primary end point (30 percent or greater reduction in 2 of 3 scores evaluating dryness, pain, and fatigue) was 17.9 percent (10/56) in the hydroxychloroquine group and 17.2 percent (11/64) in the . Use of hydroxychloroquine was also not associated with improvement in certain lab tests used to monitor the activity of Sjögren (anti-SSA antibodies, IgG levels). During the first 24 weeks, there were 2 serious adverse events in the hydroxychloroquine group and 3 in the placebo group. In the last 24 weeks, there were 3 in the hydroxychloroquine group and 4 in the placebo group.

"In the present study, hydroxychloroquine did not demonstrate efficacy for the main disabling symptoms—dryness, pain, and fatigue—of primary Sjögren syndrome compared with . [This trial] extends the negative results of the only previous controlled crossover trial, which included 19 patients and confirms that previous open trials might have overestimated the of hydroxychloroquine in primary Sjögren syndrome," the authors write.

"Further studies are needed to evaluate longer-term outcomes."

Explore further: Teduglutide seems effective, safe for short bowel syndrome

More information: DOI: 10.1001/jama.2014.7682

Related Stories

Teduglutide seems effective, safe for short bowel syndrome

December 12, 2012

(HealthDay)—For patients with short bowel syndrome with intestinal failure (SBS-IF), the glucagon-like peptide 2 analogue teduglutide appears to be safe and reduces the number of days off parenteral support, according to ...

Long-term antibiotic treatment for Q fever causes weight gain

April 14, 2014

Scientists have unearthed still more evidence that antibiotics can contribute to obesity. Research published ahead of print in the journal Antimicrobial Agents and Chemotherapy suggests that patients on long-term antibiotic ...

Recommended for you

Cellphone data can track infectious diseases

August 20, 2015

Tracking mobile phone data is often associated with privacy issues, but these vast datasets could be the key to understanding how infectious diseases are spread seasonally, according to a study published in the Proceedings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.